• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioNTech SE - American Depositary Shares (NQ:BNTX)

    94.23 +0.70 (+0.75%)
    Streaming Delayed Price Updated: 9:35 AM EDT, Jul 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 25,283
    Open 93.47
    Bid (Size) 93.98 (300)
    Ask (Size) 94.46 (100)
    Prev. Close 93.53
    Today's Range 93.39 - 94.39
    52wk Range 79.52 - 124.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
    They may not remain cheap for too much longer. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗
    It has been a banner year for biotech buyouts, and these are two of the prime targets. 
    Via The Motley Fool

    Performance

    YTD
    -2.5%
    -2.5%
    1 Month
    +10.2%
    +10.2%
    3 Month
    +2.3%
    +2.3%
    6 Month
    -5.8%
    -5.8%
    1 Year
    -15.6%
    -15.6%

    More News

    Read More
    News headline image
    Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
    From BioNTech SE
    Via GlobeNewswire
    BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides ↗
    Via Chartmill
    BioNTech SE (NASDAQ:BNTX) Stock Plummets 17% on Q4 Loss and Co-Founders' Planned Exit ↗
    Via Chartmill
    News headline image
    BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM ↗
    Via MarketBeat
    News headline image
    3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
    Via The Motley Fool
    News headline image
    Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    BioNTech Announces New ADS Repurchase Program
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗
    Via The Motley Fool
    News headline image
    BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
    Via Finterra
    Topics Initial Public Offering
    News headline image
    BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
    Via MarketMinute
    Topics Artificial Intelligence Initial Public Offering Stocks
    News headline image
    Why BioNTech Stock Is Getting Crushed Today ↗
    Via The Motley Fool
    Gapping stocks in Tuesday's session ↗
    Via Chartmill
    News headline image
    BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
    Via MarketMinute
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Why Did BNTX Stock Tumble 17% Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
    From BioNTech SE
    Via GlobeNewswire
    News headline image
    BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
    From BioNTech SE
    Via GlobeNewswire

    Frequently Asked Questions

    Is BioNTech SE - American Depositary Shares publicly traded?
    Yes, BioNTech SE - American Depositary Shares is publicly traded.
    What exchange does BioNTech SE - American Depositary Shares trade on?
    BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for BioNTech SE - American Depositary Shares?
    The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
    What is the current price of BioNTech SE - American Depositary Shares?
    The current price of BioNTech SE - American Depositary Shares is 94.23
    When was BioNTech SE - American Depositary Shares last traded?
    The last trade of BioNTech SE - American Depositary Shares was at 07/09/26 09:35 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.